Association between genotype and drug resistance profiles of Mycobacterium tuberculosis strains circulating in China in a national drug resistance survey

PLoS One. 2017 Mar 23;12(3):e0174197. doi: 10.1371/journal.pone.0174197. eCollection 2017.

Abstract

We describe the population structure of a representative collection of 3,133 Mycobacterium tuberculosis isolates, collected within the framework of a national resistance survey from 2007 in China. Genotyping data indicate that the epidemic strains in China can be divided into seven major complexes, of which 92% belonged to the East Asian (mainly Beijing strains) or the Euro-American lineage. The epidemic Beijing strains in China are closely related to the Beijing B0/W148 strain earlier described in Russia and a large cluster of these strains has spread national wide. The density of Beijing strains is high in the whole of China (average 70%), but the highest prevalence was found North of the Yellow river. The Euro-American lineage consists of three sublineages (sublineage_1, 2, and 3) and is more prevalent in the South. Beijing lineage showed the highest cluster rate of 48% and a significantly higher level of resistance to rifampicin (14%, p<0.001), ethambutol (9%, p = 0.001), and ofloxacin (5%, p = 0.011). Within the Euro-American Lineage, sublineage_3 revealed the highest cluster rate (28%) and presented a significantly elevated level of resistance to streptomycin (44%, p<0.001). Our findings suggest that standardised treatment in this region may have contributed to the successful spread of certain strains: sublineage_3 in the Euro-American lineage may have thrived when streptomycin was used without rifampicin for treatment, while later under DOTS based treatment, in which rifampicin plays a key role, Beijing lineage appears to be spreading.

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • China / epidemiology
  • Genotype
  • Humans
  • Microbial Sensitivity Tests
  • Minisatellite Repeats / genetics
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / genetics*
  • Rifampin / therapeutic use
  • Streptomycin / therapeutic use
  • Surveys and Questionnaires
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • Tuberculosis, Multidrug-Resistant / genetics*

Substances

  • Antitubercular Agents
  • Rifampin
  • Streptomycin

Grants and funding

This work was supported by the National Science and Technology Key Program (2014ZX10003002), China. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.